BioXcel Therapeutics Inc. (BTAI)’s Financial Results Comparing With Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Both BioXcel Therapeutics Inc. (NASDAQ:BTAI) and Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) are each other’s competitor in the Biotechnology industry. Thus the contrast of their profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioXcel Therapeutics Inc. 10 0.00 N/A -1.42 0.00
Aurinia Pharmaceuticals Inc. 6 1307.20 N/A -0.71 0.00

We can see in table 1 the earnings per share, top-line revenue and valuation of BioXcel Therapeutics Inc. and Aurinia Pharmaceuticals Inc.


Table 2 provides us BioXcel Therapeutics Inc. and Aurinia Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
BioXcel Therapeutics Inc. 0.00% -53.2% -48.5%
Aurinia Pharmaceuticals Inc. 0.00% 0% 0%

Analyst Ratings

In next table is delivered BioXcel Therapeutics Inc. and Aurinia Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
BioXcel Therapeutics Inc. 0 0 0 0.00
Aurinia Pharmaceuticals Inc. 0 0 5 3.00

Competitively the consensus price target of Aurinia Pharmaceuticals Inc. is $15, which is potential 127.62% upside.

Institutional & Insider Ownership

BioXcel Therapeutics Inc. and Aurinia Pharmaceuticals Inc. has shares owned by institutional investors as follows: 21.3% and 0%. BioXcel Therapeutics Inc.’s share owned by insiders are 61.71%.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
BioXcel Therapeutics Inc. -1.19% -4.52% 3.96% 96.53% 13.49% 179.02%
Aurinia Pharmaceuticals Inc. 2.42% -1.24% 4.43% 0% 19.77% -6.74%

For the past year BioXcel Therapeutics Inc. had bullish trend while Aurinia Pharmaceuticals Inc. had bearish trend.


Aurinia Pharmaceuticals Inc. beats on 5 of the 8 factors BioXcel Therapeutics Inc.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is headquartered in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.